Please login to the form below

Not currently logged in
Email:
Password:

FDA approves updated US prescribing information for Avandia and Actos

The FDA has approved updated US prescribing information for the thiazolidinediones class of medicines used in the treatment of type 2 diabetes, which include Avandia and Actos

The FDA has approved updated US prescribing information for the thiazolidinediones (TZD) class of medicines used in the treatment of type 2 diabetes, which include GlaxoSmithKline's Avandia (roseglitazone) and Takeda's Actos (pioglitazone). 

The approval thus allows GSK and Takeda to implement changes in the label for the drugs concerned. The new label will contain a boxed warning, which increases the prominence of an already existing warning for all medicines in the TZD class on the risk of congestive heart failure (CHF).

The boxed warning states that TZDs are not recommended in patients with symptomatic heart failure and that initiation of TZDs in patients with established NYHA Class III or IV heart failure is contraindicated. The side-effect profile has also been updated regarding initiation of Avandia in patients with NYHA Class III or IV heart failure.

Information about CHF has been included in the prescribing information for Avandia since 1999, when the medicine was first approved by the FDA. 

Since 2001, US prescribing information for Avandia has included a warning for "Cardiac Failure and Other Cardiac Effects" with a recommendation that use of Avandia be discontinued in patients if their cardiac health becomes worse.

The changes related to CHF are being implemented on the labels of all rosiglitazone/ pioiglitazone-containing products, including Avandia, Avandamet (rosiglitazone and metformin), Avandaryl (rosiglitazone and glimepiride), as well as Actos and its other formulations.

15th August 2007

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Lifting the fog to help Clinical Labs navigate IVDR 2022
In Vitro Diagnostic Regulation (IVDR 2022) was on the horizon: a new regulatory basis for laboratories to adhere to regarding their diagnostic equipment and tests. BD wanted to let their...
Empowering adolescents to manage emotional and mental health issues
1 in 10 UK children suffer with a mental health issue and alarmingly as many as 70% of these don’t receive the proper support they need. That’s why The Anna...
Reframing rare to increase earlier diagnosis of Gaucher Disease
Sanofi Genzyme wanted to reach haematologists; the specialist physicians most likely to encounter patients with Gaucher Disease prior to diagnosis. The problem? Gaucher Disease is considered very rare and its...